Comprehensive Neuro-Oncology Program @MayoClinic in AZ, Medical Director @MrugalaMaciej Tweet about brain/spine tumors & our collaborative program. tweets=ours
Apply today for the 8th Annual Clinical Trial Design and Protocol Development Workshop! The deadline is May 15, 2026. For more info: https://t.co/VkFumTCsQm
#SNO2026#NeuroOncology#ClinicalTrials
Happy New Year! ✨ The New Year invites us to reflect, recharge, and look ahead with hope. May the coming year bring happiness, purpose, and wellness to you and those you love.
At our 7th Annual #ClinicalTrial Design and Protocol Development Workshop, attendees are learning best practices for trial design, activation, and communication across multi-disciplinary teams. #SNO2025
Time is an under-recognised social determinant of brain health.
In The Lancet Healthy Longevity, authors call for temporal justice through research and policies that recognise time as both a resource and a site of inequity in ageing and dementia: https://t.co/S3AVviAnZY
Congratulations to the 2025 @NobelPrize winners in Physiology or Medicine Brunkow, Ramsdell, and Sakaguchi for the discovery of peripheral immune tolerance. In tumor immunology, we are very familiar with FOXP3+ Tregs and their immunosuppressive roles 🧵
The hippocampus is one of the most studied brain areas because of its major role in fundamental brain functions including learning, memory, and spatial navigation.
In a new #ScienceReview, researchers focus on the role of overlooked areas and circuits within the hippocampus. https://t.co/e1q1sKavq8
📣 Calling all members!
Check your email inbox for an important survey from the Academy. Share your thoughts to help us provide resources, services, and support that fit your needs.
#Neurology#NeuroTwitter
Do you have clinical and research interests in #meningiomas, and want to find out more about becoming an #ICOM member?
Contact us today: https://t.co/YhXw2bihl4
Dr. Terry Burns, neurosurgeon at Mayo Clinic in Rochester, MN, shares how advances in brain tumor research are giving patients more hope, and why pushing the boundaries of treatment innovation remains critical.
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results | Nature Medicine https://t.co/FatLl5c3ui
There's still time to apply for the SNO and Oxford University Press Editorial Scholar’s Program. This opportunity is offered to early career members to enhance their skills as reviewers of manuscripts for the Society’s journals. For more information and to apply: https://t.co/1NFTcF7uLN